These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3672012)

  • 1. Evolution and severity markers in 233 MS patients.
    Bernardi S; Buttinelli C; Grasso MG; Millefiorini E; Pace A; Prencipe M; Fieschi C
    Riv Neurol; 1987; 57(3):197-200. PubMed ID: 3672012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age at disability milestones in multiple sclerosis.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):595-605. PubMed ID: 16415309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
    El-Salem K; Khader Y
    Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognosis in multiple sclerosis].
    Kesselring J
    Schweiz Med Wochenschr; 1997 Mar; 127(12):500-5. PubMed ID: 9148400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.
    Ghezzi A; Bergamaschi R; Martinelli V; Trojano M; Tola MR; Merelli E; Mancardi L; Gallo P; Filippi M; Zaffaroni M; Comi G;
    J Neurol; 2004 Jan; 251(1):47-52. PubMed ID: 14999489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Forms of disease progression and prognostic factors in multiple sclerosis].
    Meyer-Rienecker HJ; Hitzschke B; Buddenhagen F; Lakner K
    Psychiatr Neurol Med Psychol (Leipz); 1988 Oct; 40(10):588-97. PubMed ID: 3237865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.
    Glad SB; Nyland HI; Aarseth JH; Riise T; Myhr KM
    Mult Scler; 2009 Aug; 15(8):942-50. PubMed ID: 19570821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain.
    Morís G; Berciano J; Miró J
    Neurologia; 2003 Dec; 18(10):723-30. PubMed ID: 14648348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Late onset multiple sclerosis].
    Delalande S; De Seze J; Ferriby D; Stojkovic T; Vermersch P
    Rev Neurol (Paris); 2002 Nov; 158(11):1082-7. PubMed ID: 12451340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
    Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
    Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France.
    Debouverie M
    J Neurol Sci; 2009 Nov; 286(1-2):14-7. PubMed ID: 19691994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis in Iraq: does it have the same features encountered in Western countries?
    Al-Araji A; Mohammed AI
    J Neurol Sci; 2005 Jul; 234(1-2):67-71. PubMed ID: 15946690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical course of multiple sclerosis patients in Hong Kong.
    Lau KK; Wong WW; Sheng B; Yu IT; Fung BH; Li HL; Ma KF; Wong LK; Li PC
    J Neurol Sci; 2008 May; 268(1-2):78-82. PubMed ID: 18068191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.